Newborn Metabolic Screening Market
Newborn Metabolic Screening Market Study by Galactosemia, Sickle Cell Disease, Cystic Fibrosis, Toxoplasmosis, Methylmalonic Acidemia, Maple Syrup Urine Disease, and Others from 2024 to 2034
Analysis of Newborn Metabolic Screening Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Newborn Metabolic Screening Market Outlook (2024 to 2034)
The newborn metabolic screening market size is anticipated to hit US$ 355.1 million in 2024. A promising compound annual growth rate (CAGR) of 9.2% is projected to boost the market through 2034. This upward motion is estimated to lead the market to a significant valuation of US$ 857.4 million by 2034.
As understanding of metabolic issues affecting newborns has grown, so has the application of newborn metabolic screening tests. This is due to its ability to accurately assess a baby's health and identify a range of conditions or birth abnormalities, allowing for the provision of the necessary medical care and possibly even the baby's survival. As a result, throughout the forecast period, there is likely to be a rise in the demand for neonatal metabolic screening.
The World Health Organization estimates that birth abnormalities prompt the deaths of around 240,000 newborns in the first 28 days after birth yearly throughout the globe, and an additional 170,000 children aged one month to five years. These estimates are based on data from February 2022.
Don't Need a Global Report?
save 40%! on Country & Region specific reports
Key Newborn Metabolic Screening Market Growth Factors
- Rising global birth rates and expanding neonatal care facilities create a larger pool of potential consumers for newborn metabolic screening services.
- The increasing prevalence of metabolic disorders in newborns amplifies the demand for efficient screening methods, fostering market development.
- Growing awareness among healthcare professionals and parents about the importance of early detection of metabolic disorders fuels the demand for screening services.
- Initiatives by several governments to implement comprehensive newborn screening programs also contribute to market expansion.
- To halt the rise in infant mortality, organizations such as the WHO, CDC, Healthy Newborn Network, etc., are educating parents about possible issues and related testing procedures.
- Advances in technology have significantly improved the accuracy and efficiency of newborn metabolic screening, driving newborn metabolic screening market revenue.
| Report Attributes | Details |
|---|---|
| Estimated Market Value (2024E) | US$ 355.1 million |
| Forecasted Market Value (2034F) | US$ 857.4 million |
| Global Market Growth Rate (2024 to 2034) | 9.2% CAGR |
| Tyrosinemia Segment Growth Rate (2024 to 2034) | 13.6% |
| Hospital Segment Growth Rate (2024 to 2034) | 10.0% |
| North America Market Share (2024) | 31.0% |
| East Asia Market Share (2024) | 11.3% |
| Key Companies Profiled |
|
What are the Key Dynamics Encouraging the Newborn Metabolic Screening Market Growth?
“Rising Rates of Metabolic Disorders Propel Surge in Newborn Metabolic Screening Demand”
The increasing prevalence of metabolic disorders and genetic conditions in newborns drives the market's growth. As the incidence of these disorders rises, the demand for comprehensive newborn metabolic screening continues to surge. For instance, 44 boys and 27 girls out of 300,849 neonates in China had neonatal metabolic illness diagnostics in 2021.
Neonate metabolic screening is becoming ever more necessary because of the increased risk of sickle cell disease, phenylketonuria, galactosemia, maple syrup urine illness, and cystic fibrosis.
Newborn screening has advanced, going from a simple blood and urine test to a more comprehensive and intricate screening method that can identify over 50 distinct abnormalities. As healthcare providers recognize the value of early detection and intervention, the demand for comprehensive screening solutions continues to rise, directing the newborn metabolic screening market statistic upward.
“Newborn Metabolic Screening Mandates Gain Traction Amid Global Shift toward Early Intervention”
Governments and private groups have recognized that these medical conditions can pose a threat to a newborn's life if left untreated. They are thus making an effort to put metabolic screening programs into place to address the issues at hand. For example, Ayushman Bharat, one of the top people-centered initiatives, was launched in India.
Governments and organizations are carrying out different strategies and developments to deal with issues in the newborn and maternal health sector in India. Moreover, newborn screening has been mandated in several countries. For instance, Italy has directed newborn screening for over 40 congenital metabolic disorders since 2016.
The 2004 Newborn Screening Act in the Philippines mandates newborn screening as a fundamental component of newborn care. The implementation of such policies ensures that a larger proportion of newborns undergo screening, contributing to the market expansion.
“Advanced Technologies like Next-generation Sequencing are Transforming Newborn Metabolic Screening”
The market is projected to grow as a result of the release of advanced newborn metabolic screening technologies. Newborn metabolic screening market trends are shaping the future of personalized care for infants. In recent advances, next-generation sequencing (NGS) has revolutionized genetic analysis, rapidly sequencing numerous genes or entire genomes.
Widely applied in medical contexts, NGS enhances disease diagnosis, prognosis, and therapeutic decision-making, offering unparalleled accuracy and enabling early detection of previously overlooked disorders.
Another crucial technique is mass spectrometry (MS). Identifying and quantifying various therapeutically important analytes is possible with the use of MS, a potent qualitative and quantitative analytical method. Multiple biomarkers can be measured simultaneously using MS for newborn metabolic screening.
This testing approach improves the identification of several illnesses. These advancements show a path toward transformation and emphasize how important these tests are to the direction that pediatric healthcare is taking.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Which Factors Pose Challenges to the Development of the Newborn Metabolic Screening Market?
“Lack of Healthcare Modernization and Skilled Professionals Impact the Market Negatively”
The primary constraints obstructing the newborn screening market expansion are the healthcare sector's lack of modernization of infrastructure and a scarcity of people with the education and experience needed. For example, since newborn screening is still not widely employed in the Asia Pacific, further study and tutoring are required.
Developing countries with sizable populations and a dearth of skilled workers are present. Improved healthcare systems in developing countries are hampered by high population densities, low and intermediate income levels, and inadequate medical treatment.
“False Test Findings and Standardization Issues Limit the Newborn Metabolic Screening Industry Expansion”
The newborn metabolic screening market is also expected to be hindered throughout the forecast period by a high percentage of false positive and false negative test findings, as well as a lack of global standardization in newborn metabolic screening policies and procedures.
The lack of follow-up data for screening diseases and the lack of knowledge on the long-term implications of newly discovered illnesses make it difficult for medical professionals to make decisions. Furthermore, the availability of reconditioned products, such as automated manual equipment and immunoassay systems, is expected to restrict the market expansion to a certain extent throughout 2034.
Country-wise Insights
The North America newborn metabolic screening market is gearing up for promising growth, prophesying a steady CAGR of 9.4% through 2034. This is because of the high rate of birth abnormalities in the region, strict local government regulations, an excellent healthcare system, and recent innovations in newborn metabolic screening technologies made by regional players. In this region, the United States is set to take the lead in the newborn metabolic screening industry, holding a substantial regional market share of 78.7% in 2024.
The newborn metabolic screening market in East Asia is poised for average advancement, aiming at a 9.6% CAGR until 2034. An increase in newborn screening engagement programs by different government healthcare regulatory organizations and their implementation for a larger population base principally supports the market growth here. In 2024, China is likely to take the limelight as a key player in the newborn metabolic screening industry, boasting an estimated regional share of 67.2%.
What Factors Contribute to the United State’ Supremacy in the Global Newborn Metabolic Screening Market?
“Government-driven Newborn Screening Programs Set to Transform Market Dynamics in the United States”
The United States is well aware of newborn metabolic problems. The country has significantly changed its metabolic screening procedures. The government has made newborn metabolic screening mandatory before hospital discharge. So, government-run newborn screening programs are anticipated to have an important effect on market expansion. In the United States, the states administer newborn screening programs, including metabolic screening. For example, the March of Dimes (MoD) report from 2021 states that every infant in the United States undergoes newborn screening before exiting the hospital, with an estimated 4 million babies screened each year.
| Attributes | Details |
|---|---|
| United States Market Size (2024E) | US$ 87 million |
| United States Market Size (2034F) | US$ 220 million |
| United States Market CAGR (2024 to 2034) | 9.8% |
Companies like Danaher Corporation and PerkinElmer are proactively offering a range of newborn screening services. As the very first approved test for spinal muscular atrophy (SMA) screening in neonates, PerkinElmer reported in December 2022 that the EONISTM SCID-SMA Kit has been granted marketing authorization by the United States Food and Drug Administration.
What Factors Contribute to China’s Eminence as a Booming Market for Newborn Metabolic Screening Providers?
“Rising Incidence of Congenital Illnesses and Stress-free Insurance Coverage Boost China's Newborn Screening Industry Expansion”
Increased financing for newborn screening from government sectors is the primary factor driving the China newborn metabolic screening market. In 1981, the country launched a program for screening newborns. Newborn screening is becoming increasingly important to the government. The program for screening newborns run by the government includes collecting samples, laboratory testing, clinical diagnosis, reporting of results, follow-up, and delivery. The market expansion has been significantly aided by the coverage of some tests by regional medical insurance plans and initiatives for charitable organizations.
| Attributes | Details |
|---|---|
| China Market Size (2024E) | US$ 27 million |
| China Market Size (2034F) | US$ 70 million |
| China Market CAGR (2024 to 2034) | 9.9% |
An increase in the incidence of congenital illness, expanding newborn screening programs, and technological developments in newborn metabolic screening are some of the other crucial factors driving the expansion of the newborn screening market. As per the findings of a research paper released in April 2022, ‘Epidemiology of Congenital Heart Disease in Jinan, China From 2005 to 2020: A Time Trend Analysis,’ the overall incidence of congenital heart disease increased by 157.45% and 316.03%, correspondingly, in both urban and rural areas from 2005 to 2020. In towns and cities, the frequency of coronary artery diseases was 4.81 per 1,000 births, while it was 3.17 per 1,000 births in the countryside.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Category-wise Insights
In 2024, the sickle cell disease test type segment is projected to be at the forefront, claiming a substantial 32.5% share of the market. On the other hand, the hospital segment is set to assert its dominance in the newborn metabolic screening industry, commanding a notable 40.3% market share in 2024.
Why is the Sickle Cell Disease Test Type Preferred in the Newborn Metabolic Screening Industry?
“Sickle Cell Disease Screening Gains Momentum with Innovative Tests and Community Outreach”
The sickle cell disease segment is estimated to hold a 30.3% share of the newborn metabolic screening market by 2034. The adoption of the sickle cell disease test type is projected to upsurge at a CAGR of 8.4% through 2034. Sickle cell disease is more common in newborns. In the United States, sickle cell disease affects about 2,000 newborns annually. This makes screening crucial for early assessment.
Increased development of new types of tests for sickle cell disease screening are also responsible for this. For example, to increase newborn screening for sickle cell disease (SCD) in sub-Saharan Africa, Revvity Inc. (PerkinElmer Inc.) partnered with Novartis AG, a renowned global pharmaceutical firm, in June 2022.
Expanding grassroots campaigns to raise awareness among patients, caregivers, and communities about the value of early intervention with hydroxyurea (HU) and other SCD medications, as well as newborn screening, is the goal of Revvity and Novartis.
During the forecast period, however, the tyrosinemia test type is anticipated to witness rapid adoption. Transient tyrosinemia, or momentarily high tyrosine levels in infants, affects around 1 in 10 infants, as reported by the National Organization for Rare Disorders.
Since tyrosinemia testing can identify this rare genetic condition early on, it is becoming ever more common in newborn screenings. This test facilitates early intervention and therapy by assisting in the identification of increased tyrosine levels.
What Factors Drive the Swift Embrace of Newborn Metabolic Screening in Hospital Settings?
“Hospitals Emerged as Prime Hubs for Newborn Screening Given their Specialized Staff and Location Appeal”
The hospital segment is likely to grip 43.4% of the newborn metabolic screening market share by 2034. The adoption of newborn metabolic screening in hospitals is anticipated to rise at a CAGR of 10.0% through 2034. This marks the maximum growth rate among end users, underscoring the increasing recognition of the screening's significance in hospitals.
Hospitals are the preferred location for giving birth. Their superior infrastructure, use of cutting-edge medical procedures, and availability of highly qualified personnel represent a few of the factors that account for this segment's substantial growth.
Parents choose hospitals for the reason that they have convenient locations near housing developments and have physicians on hand when required. Since hospital staff members are more demanding and have specialized training, people tend to favor them for screening and detection. They also provide a range of metabolic screening tests for your newborn baby.
Competitive Landscape
Key players in the newborn metabolic screening market include PerkinElmer, Bio-Rad Laboratories, Trivitron Healthcare Private Limited, BioMedomics, Inc., Luminex Corporation, MP BIOMEDICALS, Synergy Medical Systems LLP, Agilent Technologies, Inc., Thermo Fisher Scientific, Inc., Zivak Technologies, Covidien Plc, AB Sciex LLC, Waters Corp., Masimo Corp., and Natus Medical Inc.
Companies are purposefully aligning themselves to gain a competitive edge, anticipating the lucrative opportunities presented by the newborn metabolic screening market forecast. Some concentrate on recent advanced technology, applying sophisticated screening techniques to improve precision and increase the spectrum of illnesses that may be identified.
Some place a higher priority on pricing to reach a wider audience for screening. To be at the forefront of medical innovations, many players establish calculated connections with research institutes and healthcare providers. Businesses try to quickly adjust to new trends by maintaining a constant level of investment in research and development. In general, the competitive field is distinguished by a dedication to technological excellence, usability, and strategic partnerships.
Recent Developments
- In September 2023, Mylab Discovery Solutions unveiled MyNeoShield for Newborns, a patent-pending point-of-care device representing a revolutionary leap in newborn screening. This tool is going to change the face of newborn healthcare by lowering the cost, increasing accessibility, and speeding up screening.
- In June 2022, through a collaboration with the American Society of Hematology (ASH), Novartis AG began supplying six more African countries with the same technology now being utilized in Ghana to record and distribute sickle cell disease diagnostic data for infants. Through this collaboration, the present newborn screening consortium is going to reach new regions.
- In September 2020, top organizations dedicated to rare medical conditions, such as Orchard Therapeutics, Sarepta Therapeutics, Inc., BioMarin Pharmaceutical Inc., Retrophin, Inc., and the EveryLife Foundation for Rare Diseases, joined forces to assess how well newborn screening in the United States can diagnose all babies who received assistance from new therapies in the right way.
Segmentation of Newborn Metabolic Screening Market Analysis
-
By Test Type :
- Galactosemia
- Sickle Cell Disease
- Cystic Fibrosis
- Toxoplasmosis
- Phenylketonuria
- Methylmalonic Acidemia
- Maple Syrup Urine Disease
- Tyrosinemia
- Citrullinema, Medium Chain Acyl CoA Dehydrogenase Deficiency
-
By Sample :
- Coronary Artery Diseases
- Chronic Heart Failure
-
By End User :
- Hospitals
- Ambulatory Surgical Centers
- Independent Catherization Labs
-
By Region :
- North America
- Latin America
- East Asia
- South Asia and Pacific
- Western Europe
- Eastern Europe
- The Middle East and Africa
Table of Content
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2019-2023 and Forecast, 2024-2034 4.1. Historical Market Size Value (US$ Million) Analysis, 2019-2023 4.2. Current and Future Market Size Value (US$ Million) Projections, 2024-2034 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2019-2023 and Forecast 2024-2034, By Test 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Test, 2019-2023 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Test, 2024-2034 5.3.1. Galactosemia 5.3.2. Sickle Cell Disease 5.3.3. Cystic Fibrosis 5.3.4. Toxoplasmosis 5.3.5. Phenylketonuria (PKU) 5.3.6. Methylmalonic Acidemia 5.3.7. Maple Syrup Urine Disease (MSUD) 5.3.8. Tyrosinemia 5.3.9. Citrullinemia 5.3.10. Medium Chain Acyl CoA Dehydrogenase (MCAD) Deficiency 5.4. Y-o-Y Growth Trend Analysis By Test, 2019-2023 5.5. Absolute $ Opportunity Analysis By Test, 2024-2034 6. Global Market Analysis 2019-2023 and Forecast 2024-2034, By Sample 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Sample, 2019-2023 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Sample, 2024-2034 6.3.1. Blood 6.3.2. Urine 6.4. Y-o-Y Growth Trend Analysis By Sample, 2019-2023 6.5. Absolute $ Opportunity Analysis By Sample, 2024-2034 7. Global Market Analysis 2019-2023 and Forecast 2024-2034, By End User 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) Analysis By End User , 2019-2023 7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User , 2024-2034 7.3.1. Diagnostic Laboratories 7.3.2. Specialty Clinics 7.3.3. Hospitals 7.4. Y-o-Y Growth Trend Analysis By End User , 2019-2023 7.5. Absolute $ Opportunity Analysis By End User , 2024-2034 8. Global Market Analysis 2019-2023 and Forecast 2024-2034, By Region 8.1. Introduction 8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2019-2023 8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2024-2034 8.3.1. North America 8.3.2. Latin America 8.3.3. Western Europe 8.3.4. Eastern Europe 8.3.5. South Asia and Pacific 8.3.6. East Asia 8.3.7. Middle East and Africa 8.4. Market Attractiveness Analysis By Region 9. North America Market Analysis 2019-2023 and Forecast 2024-2034, By Country 9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019-2023 9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024-2034 9.2.1. By Country 9.2.1.1. U.S. 9.2.1.2. Canada 9.2.2. By Test 9.2.3. By Sample 9.2.4. By End User 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Test 9.3.3. By Sample 9.3.4. By End User 9.4. Key Takeaways 10. Latin America Market Analysis 2019-2023 and Forecast 2024-2034, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019-2023 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024-2034 10.2.1. By Country 10.2.1.1. Brazil 10.2.1.2. Mexico 10.2.1.3. Rest of Latin America 10.2.2. By Test 10.2.3. By Sample 10.2.4. By End User 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Test 10.3.3. By Sample 10.3.4. By End User 10.4. Key Takeaways 11. Western Europe Market Analysis 2019-2023 and Forecast 2024-2034, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019-2023 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024-2034 11.2.1. By Country 11.2.1.1. Germany 11.2.1.2. U.K. 11.2.1.3. France 11.2.1.4. Spain 11.2.1.5. Italy 11.2.1.6. Rest of Western Europe 11.2.2. By Test 11.2.3. By Sample 11.2.4. By End User 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Test 11.3.3. By Sample 11.3.4. By End User 11.4. Key Takeaways 12. Eastern Europe Market Analysis 2019-2023 and Forecast 2024-2034, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019-2023 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024-2034 12.2.1. By Country 12.2.1.1. Poland 12.2.1.2. Russia 12.2.1.3. Czech Republic 12.2.1.4. Romania 12.2.1.5. Rest of Eastern Europe 12.2.2. By Test 12.2.3. By Sample 12.2.4. By End User 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Test 12.3.3. By Sample 12.3.4. By End User 12.4. Key Takeaways 13. South Asia and Pacific Market Analysis 2019-2023 and Forecast 2024-2034, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019-2023 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024-2034 13.2.1. By Country 13.2.1.1. India 13.2.1.2. Bangladesh 13.2.1.3. Australia 13.2.1.4. New Zealand 13.2.1.5. Rest of South Asia and Pacific 13.2.2. By Test 13.2.3. By Sample 13.2.4. By End User 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Test 13.3.3. By Sample 13.3.4. By End User 13.4. Key Takeaways 14. East Asia Market Analysis 2019-2023 and Forecast 2024-2034, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019-2023 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024-2034 14.2.1. By Country 14.2.1.1. China 14.2.1.2. Japan 14.2.1.3. South Korea 14.2.2. By Test 14.2.3. By Sample 14.2.4. By End User 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Test 14.3.3. By Sample 14.3.4. By End User 14.4. Key Takeaways 15. Middle East and Africa Market Analysis 2019-2023 and Forecast 2024-2034, By Country 15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019-2023 15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024-2034 15.2.1. By Country 15.2.1.1. GCC Countries 15.2.1.2. South Africa 15.2.1.3. Israel 15.2.1.4. Rest of MEA 15.2.2. By Test 15.2.3. By Sample 15.2.4. By End User 15.3. Market Attractiveness Analysis 15.3.1. By Country 15.3.2. By Test 15.3.3. By Sample 15.3.4. By End User 15.4. Key Takeaways 16. Key Countries Market Analysis 16.1. U.S. 16.1.1. Pricing Analysis 16.1.2. Market Share Analysis, 2023 16.1.2.1. By Test 16.1.2.2. By Sample 16.1.2.3. By End User 16.2. Canada 16.2.1. Pricing Analysis 16.2.2. Market Share Analysis, 2023 16.2.2.1. By Test 16.2.2.2. By Sample 16.2.2.3. By End User 16.3. Brazil 16.3.1. Pricing Analysis 16.3.2. Market Share Analysis, 2023 16.3.2.1. By Test 16.3.2.2. By Sample 16.3.2.3. By End User 16.4. Mexico 16.4.1. Pricing Analysis 16.4.2. Market Share Analysis, 2023 16.4.2.1. By Test 16.4.2.2. By Sample 16.4.2.3. By End User 16.5. Germany 16.5.1. Pricing Analysis 16.5.2. Market Share Analysis, 2023 16.5.2.1. By Test 16.5.2.2. By Sample 16.5.2.3. By End User 16.6. U.K. 16.6.1. Pricing Analysis 16.6.2. Market Share Analysis, 2023 16.6.2.1. By Test 16.6.2.2. By Sample 16.6.2.3. By End User 16.7. France 16.7.1. Pricing Analysis 16.7.2. Market Share Analysis, 2023 16.7.2.1. By Test 16.7.2.2. By Sample 16.7.2.3. By End User 16.8. Spain 16.8.1. Pricing Analysis 16.8.2. Market Share Analysis, 2023 16.8.2.1. By Test 16.8.2.2. By Sample 16.8.2.3. By End User 16.9. Italy 16.9.1. Pricing Analysis 16.9.2. Market Share Analysis, 2023 16.9.2.1. By Test 16.9.2.2. By Sample 16.9.2.3. By End User 16.10. Poland 16.10.1. Pricing Analysis 16.10.2. Market Share Analysis, 2023 16.10.2.1. By Test 16.10.2.2. By Sample 16.10.2.3. By End User 16.11. Russia 16.11.1. Pricing Analysis 16.11.2. Market Share Analysis, 2023 16.11.2.1. By Test 16.11.2.2. By Sample 16.11.2.3. By End User 16.12. Czech Republic 16.12.1. Pricing Analysis 16.12.2. Market Share Analysis, 2023 16.12.2.1. By Test 16.12.2.2. By Sample 16.12.2.3. By End User 16.13. Romania 16.13.1. Pricing Analysis 16.13.2. Market Share Analysis, 2023 16.13.2.1. By Test 16.13.2.2. By Sample 16.13.2.3. By End User 16.14. India 16.14.1. Pricing Analysis 16.14.2. Market Share Analysis, 2023 16.14.2.1. By Test 16.14.2.2. By Sample 16.14.2.3. By End User 16.15. Bangladesh 16.15.1. Pricing Analysis 16.15.2. Market Share Analysis, 2023 16.15.2.1. By Test 16.15.2.2. By Sample 16.15.2.3. By End User 16.16. Australia 16.16.1. Pricing Analysis 16.16.2. Market Share Analysis, 2023 16.16.2.1. By Test 16.16.2.2. By Sample 16.16.2.3. By End User 16.17. New Zealand 16.17.1. Pricing Analysis 16.17.2. Market Share Analysis, 2023 16.17.2.1. By Test 16.17.2.2. By Sample 16.17.2.3. By End User 16.18. China 16.18.1. Pricing Analysis 16.18.2. Market Share Analysis, 2023 16.18.2.1. By Test 16.18.2.2. By Sample 16.18.2.3. By End User 16.19. Japan 16.19.1. Pricing Analysis 16.19.2. Market Share Analysis, 2023 16.19.2.1. By Test 16.19.2.2. By Sample 16.19.2.3. By End User 16.20. South Korea 16.20.1. Pricing Analysis 16.20.2. Market Share Analysis, 2023 16.20.2.1. By Test 16.20.2.2. By Sample 16.20.2.3. By End User 16.21. GCC Countries 16.21.1. Pricing Analysis 16.21.2. Market Share Analysis, 2023 16.21.2.1. By Test 16.21.2.2. By Sample 16.21.2.3. By End User 16.22. South Africa 16.22.1. Pricing Analysis 16.22.2. Market Share Analysis, 2023 16.22.2.1. By Test 16.22.2.2. By Sample 16.22.2.3. By End User 16.23. Israel 16.23.1. Pricing Analysis 16.23.2. Market Share Analysis, 2023 16.23.2.1. By Test 16.23.2.2. By Sample 16.23.2.3. By End User 17. Market Structure Analysis 17.1. Competition Dashboard 17.2. Competition Benchmarking 17.3. Market Share Analysis of Top Players 17.3.1. By Regional 17.3.2. By Test 17.3.3. By Sample 17.3.4. By End User 18. Competition Analysis 18.1. Competition Deep Dive 18.1.1. Bio-Rad Laboratories 18.1.1.1. Overview 18.1.1.2. Product Portfolio 18.1.1.3. Profitability by Market Segments 18.1.1.4. Sales Footprint 18.1.1.5. Strategy Overview 18.1.1.5.1. Marketing Strategy 18.1.2. Trivitron Healthcare Private Limited 18.1.2.1. Overview 18.1.2.2. Product Portfolio 18.1.2.3. Profitability by Market Segments 18.1.2.4. Sales Footprint 18.1.2.5. Strategy Overview 18.1.2.5.1. Marketing Strategy 18.1.3. BioMedomics, Inc. 18.1.3.1. Overview 18.1.3.2. Product Portfolio 18.1.3.3. Profitability by Market Segments 18.1.3.4. Sales Footprint 18.1.3.5. Strategy Overview 18.1.3.5.1. Marketing Strategy 18.1.4. Luminex Corporation 18.1.4.1. Overview 18.1.4.2. Product Portfolio 18.1.4.3. Profitability by Market Segments 18.1.4.4. Sales Footprint 18.1.4.5. Strategy Overview 18.1.4.5.1. Marketing Strategy 18.1.5. Natus Medical Inc. 18.1.5.1. Overview 18.1.5.2. Product Portfolio 18.1.5.3. Profitability by Market Segments 18.1.5.4. Sales Footprint 18.1.5.5. Strategy Overview 18.1.5.5.1. Marketing Strategy 18.1.6. Synergy Medical Systems LLP 18.1.6.1. Overview 18.1.6.2. Product Portfolio 18.1.6.3. Profitability by Market Segments 18.1.6.4. Sales Footprint 18.1.6.5. Strategy Overview 18.1.6.5.1. Marketing Strategy 18.1.7. Agilent Technologies, Inc 18.1.7.1. Overview 18.1.7.2. Product Portfolio 18.1.7.3. Profitability by Market Segments 18.1.7.4. Sales Footprint 18.1.7.5. Strategy Overview 18.1.7.5.1. Marketing Strategy 18.1.8. Thermo Fisher Scientific, Inc 18.1.8.1. Overview 18.1.8.2. Product Portfolio 18.1.8.3. Profitability by Market Segments 18.1.8.4. Sales Footprint 18.1.8.5. Strategy Overview 18.1.8.5.1. Marketing Strategy 18.1.9. Zivak Technologies 18.1.9.1. Overview 18.1.9.2. Product Portfolio 18.1.9.3. Profitability by Market Segments 18.1.9.4. Sales Footprint 18.1.9.5. Strategy Overview 18.1.9.5.1. Marketing Strategy 18.1.10. Covidien Plc 18.1.10.1. Overview 18.1.10.2. Product Portfolio 18.1.10.3. Profitability by Market Segments 18.1.10.4. Sales Footprint 18.1.10.5. Strategy Overview 18.1.10.5.1. Marketing Strategy 19. Assumptions & Acronyms Used 20. Research Methodology
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 1: Global Market Value (US$ Million) Forecast by Region, 2019-2034
Table 2: Global Market Value (US$ Million) Forecast by Test, 2019-2034
Table 3: Global Market Value (US$ Million) Forecast by Sample, 2019-2034
Table 4: Global Market Value (US$ Million) Forecast by End User, 2019-2034
Table 5: North America Market Value (US$ Million) Forecast by Country, 2019-2034
Table 6: North America Market Value (US$ Million) Forecast by Test, 2019-2034
Table 7: North America Market Value (US$ Million) Forecast by Sample, 2019-2034
Table 8: North America Market Value (US$ Million) Forecast by End User , 2019-2034
Table 9: Latin America Market Value (US$ Million) Forecast by Country, 2019-2034
Table 10: Latin America Market Value (US$ Million) Forecast by Test, 2019-2034
Table 11: Latin America Market Value (US$ Million) Forecast by Sample, 2019-2034
Table 12: Latin America Market Value (US$ Million) Forecast by End User , 2019-2034
Table 13: Western Europe Market Value (US$ Million) Forecast by Country, 2019-2034
Table 14: Western Europe Market Value (US$ Million) Forecast by Test, 2019-2034
Table 15: Western Europe Market Value (US$ Million) Forecast by Sample, 2019-2034
Table 16: Western Europe Market Value (US$ Million) Forecast by End User , 2019-2034
Table 17: Eastern Europe Market Value (US$ Million) Forecast by Country, 2019-2034
Table 18: Eastern Europe Market Value (US$ Million) Forecast by Test, 2019-2034
Table 19: Eastern Europe Market Value (US$ Million) Forecast by Sample, 2019-2034
Table 20: Eastern Europe Market Value (US$ Million) Forecast by End User , 2019-2034
Table 21: South Asia and Pacific Market Value (US$ Million) Forecast by Country, 2019-2034
Table 22: South Asia and Pacific Market Value (US$ Million) Forecast by Test, 2019-2034
Table 23: South Asia and Pacific Market Value (US$ Million) Forecast by Sample, 2019-2034
Table 24: South Asia and Pacific Market Value (US$ Million) Forecast by End User, 2019-2034
Table 25: East Asia Market Value (US$ Million) Forecast by Country, 2019-2034
Table 26: East Asia Market Value (US$ Million) Forecast by Test, 2019-2034
Table 27: East Asia Market Value (US$ Million) Forecast by Sample, 2019-2034
Table 28: East Asia Market Value (US$ Million) Forecast by End User , 2019-2034
Table 29: Middle East and Africa Market Value (US$ Million) Forecast by Country, 2019-2034
Table 30: Middle East and Africa Market Value (US$ Million) Forecast by Test, 2019-2034
Table 31: Middle East and Africa Market Value (US$ Million) Forecast by Sample, 2019-2034
Table 32: Middle East and Africa Market Value (US$ Million) Forecast by End User, 2019-2034
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Figure 1: Global Market Value (US$ Million) by Test, 2024-2034
Figure 2: Global Market Value (US$ Million) by Sample, 2024-2034
Figure 3: Global Market Value (US$ Million) by End User, 2024-2034
Figure 4: Global Market Value (US$ Million) by Region, 2024-2034
Figure 5: Global Market Value (US$ Million) Analysis by Region, 2019-2034
Figure 6: Global Market Value Share (%) and BPS Analysis by Region, 2024-2034
Figure 7: Global Market Y-o-Y Growth (%) Projections by Region, 2024-2034
Figure 8: Global Market Value (US$ Million) Analysis by Test, 2019-2034
Figure 9: Global Market Value Share (%) and BPS Analysis by Test, 2024-2034
Figure 10: Global Market Y-o-Y Growth (%) Projections by Test, 2024-2034
Figure 11: Global Market Value (US$ Million) Analysis by Sample, 2019-2034
Figure 12: Global Market Value Share (%) and BPS Analysis by Sample, 2024-2034
Figure 13: Global Market Y-o-Y Growth (%) Projections by Sample, 2024-2034
Figure 14: Global Market Value (US$ Million) Analysis by End User, 2019-2034
Figure 15: Global Market Value Share (%) and BPS Analysis by End User, 2024-2034
Figure 16: Global Market Y-o-Y Growth (%) Projections by End User, 2024-2034
Figure 17: Global Market Attractiveness by Test, 2024-2034
Figure 18: Global Market Attractiveness by Sample, 2024-2034
Figure 19: Global Market Attractiveness by End User, 2024-2034
Figure 20: Global Market Attractiveness by Region, 2024-2034
Figure 21: North America Market Value (US$ Million) by Test, 2024-2034
Figure 22: North America Market Value (US$ Million) by Sample, 2024-2034
Figure 23: North America Market Value (US$ Million) by End User, 2024-2034
Figure 24: North America Market Value (US$ Million) by Country, 2024-2034
Figure 25: North America Market Value (US$ Million) Analysis by Country, 2019-2034
Figure 26: North America Market Value Share (%) and BPS Analysis by Country, 2024-2034
Figure 27: North America Market Y-o-Y Growth (%) Projections by Country, 2024-2034
Figure 28: North America Market Value (US$ Million) Analysis by Test, 2019-2034
Figure 29: North America Market Value Share (%) and BPS Analysis by Test, 2024-2034
Figure 30: North America Market Y-o-Y Growth (%) Projections by Test, 2024-2034
Figure 31: North America Market Value (US$ Million) Analysis by Sample, 2019-2034
Figure 32: North America Market Value Share (%) and BPS Analysis by Sample, 2024-2034
Figure 33: North America Market Y-o-Y Growth (%) Projections by Sample, 2024-2034
Figure 34: North America Market Value (US$ Million) Analysis by End User, 2019-2034
Figure 35: North America Market Value Share (%) and BPS Analysis by End User, 2024-2034
Figure 36: North America Market Y-o-Y Growth (%) Projections by End User, 2024-2034
Figure 37: North America Market Attractiveness by Test, 2024-2034
Figure 38: North America Market Attractiveness by Sample, 2024-2034
Figure 39: North America Market Attractiveness by End User, 2024-2034
Figure 40: North America Market Attractiveness by Country, 2024-2034
Figure 41: Latin America Market Value (US$ Million) by Test, 2024-2034
Figure 42: Latin America Market Value (US$ Million) by Sample, 2024-2034
Figure 43: Latin America Market Value (US$ Million) by End User , 2024-2034
Figure 44: Latin America Market Value (US$ Million) by Country, 2024-2034
Figure 45: Latin America Market Value (US$ Million) Analysis by Country, 2019-2034
Figure 46: Latin America Market Value Share (%) and BPS Analysis by Country, 2024-2034
Figure 47: Latin America Market Y-o-Y Growth (%) Projections by Country, 2024-2034
Figure 48: Latin America Market Value (US$ Million) Analysis by Test, 2019-2034
Figure 49: Latin America Market Value Share (%) and BPS Analysis by Test, 2024-2034
Figure 50: Latin America Market Y-o-Y Growth (%) Projections by Test, 2024-2034
Figure 51: Latin America Market Value (US$ Million) Analysis by Sample, 2019-2034
Figure 52: Latin America Market Value Share (%) and BPS Analysis by Sample, 2024-2034
Figure 53: Latin America Market Y-o-Y Growth (%) Projections by Sample, 2024-2034
Figure 54: Latin America Market Value (US$ Million) Analysis by End User , 2019-2034
Figure 55: Latin America Market Value Share (%) and BPS Analysis by End User , 2024-2034
Figure 56: Latin America Market Y-o-Y Growth (%) Projections by End User, 2024-2034
Figure 57: Latin America Market Attractiveness by Test, 2024-2034
Figure 58: Latin America Market Attractiveness by Sample, 2024-2034
Figure 59: Latin America Market Attractiveness by End User, 2024-2034
Figure 60: Latin America Market Attractiveness by Country, 2024-2034
Figure 61: Western Europe Market Value (US$ Million) by Test, 2024-2034
Figure 62: Western Europe Market Value (US$ Million) by Sample, 2024-2034
Figure 63: Western Europe Market Value (US$ Million) by End User, 2024-2034
Figure 64: Western Europe Market Value (US$ Million) by Country, 2024-2034
Figure 65: Western Europe Market Value (US$ Million) Analysis by Country, 2019-2034
Figure 66: Western Europe Market Value Share (%) and BPS Analysis by Country, 2024-2034
Figure 67: Western Europe Market Y-o-Y Growth (%) Projections by Country, 2024-2034
Figure 68: Western Europe Market Value (US$ Million) Analysis by Test, 2019-2034
Figure 69: Western Europe Market Value Share (%) and BPS Analysis by Test, 2024-2034
Figure 70: Western Europe Market Y-o-Y Growth (%) Projections by Test, 2024-2034
Figure 71: Western Europe Market Value (US$ Million) Analysis by Sample, 2019-2034
Figure 72: Western Europe Market Value Share (%) and BPS Analysis by Sample, 2024-2034
Figure 73: Western Europe Market Y-o-Y Growth (%) Projections by Sample, 2024-2034
Figure 74: Western Europe Market Value (US$ Million) Analysis by End User, 2019-2034
Figure 75: Western Europe Market Value Share (%) and BPS Analysis by End User, 2024-2034
Figure 76: Western Europe Market Y-o-Y Growth (%) Projections by End User, 2024-2034
Figure 77: Western Europe Market Attractiveness by Test, 2024-2034
Figure 78: Western Europe Market Attractiveness by Sample, 2024-2034
Figure 79: Western Europe Market Attractiveness by End User, 2024-2034
Figure 80: Western Europe Market Attractiveness by Country, 2024-2034
Figure 81: Eastern Europe Market Value (US$ Million) by Test, 2024-2034
Figure 82: Eastern Europe Market Value (US$ Million) by Sample, 2024-2034
Figure 83: Eastern Europe Market Value (US$ Million) by End User, 2024-2034
Figure 84: Eastern Europe Market Value (US$ Million) by Country, 2024-2034
Figure 85: Eastern Europe Market Value (US$ Million) Analysis by Country, 2019-2034
Figure 86: Eastern Europe Market Value Share (%) and BPS Analysis by Country, 2024-2034
Figure 87: Eastern Europe Market Y-o-Y Growth (%) Projections by Country, 2024-2034
Figure 88: Eastern Europe Market Value (US$ Million) Analysis by Test, 2019-2034
Figure 89: Eastern Europe Market Value Share (%) and BPS Analysis by Test, 2024-2034
Figure 90: Eastern Europe Market Y-o-Y Growth (%) Projections by Test, 2024-2034
Figure 91: Eastern Europe Market Value (US$ Million) Analysis by Sample, 2019-2034
Figure 92: Eastern Europe Market Value Share (%) and BPS Analysis by Sample, 2024-2034
Figure 93: Eastern Europe Market Y-o-Y Growth (%) Projections by Sample, 2024-2034
Figure 94: Eastern Europe Market Value (US$ Million) Analysis by End User, 2019-2034
Figure 95: Eastern Europe Market Value Share (%) and BPS Analysis by End User, 2024-2034
Figure 96: Eastern Europe Market Y-o-Y Growth (%) Projections by End User, 2024-2034
Figure 97: Eastern Europe Market Attractiveness by Test, 2024-2034
Figure 98: Eastern Europe Market Attractiveness by Sample, 2024-2034
Figure 99: Eastern Europe Market Attractiveness by End User, 2024-2034
Figure 100: Eastern Europe Market Attractiveness by Country, 2024-2034
Figure 101: South Asia and Pacific Market Value (US$ Million) by Test, 2024-2034
Figure 102: South Asia and Pacific Market Value (US$ Million) by Sample, 2024-2034
Figure 103: South Asia and Pacific Market Value (US$ Million) by End User , 2024-2034
Figure 104: South Asia and Pacific Market Value (US$ Million) by Country, 2024-2034
Figure 105: South Asia and Pacific Market Value (US$ Million) Analysis by Country, 2019-2034
Figure 106: South Asia and Pacific Market Value Share (%) and BPS Analysis by Country, 2024-2034
Figure 107: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Country, 2024-2034
Figure 108: South Asia and Pacific Market Value (US$ Million) Analysis by Test, 2019-2034
Figure 109: South Asia and Pacific Market Value Share (%) and BPS Analysis by Test, 2024-2034
Figure 110: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Test, 2024-2034
Figure 111: South Asia and Pacific Market Value (US$ Million) Analysis by Sample, 2019-2034
Figure 112: South Asia and Pacific Market Value Share (%) and BPS Analysis by Sample, 2024-2034
Figure 113: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Sample, 2024-2034
Figure 114: South Asia and Pacific Market Value (US$ Million) Analysis by End User, 2019-2034
Figure 115: South Asia and Pacific Market Value Share (%) and BPS Analysis by End User, 2024-2034
Figure 116: South Asia and Pacific Market Y-o-Y Growth (%) Projections by End User , 2024-2034
Figure 117: South Asia and Pacific Market Attractiveness by Test, 2024-2034
Figure 118: South Asia and Pacific Market Attractiveness by Sample, 2024-2034
Figure 119: South Asia and Pacific Market Attractiveness by End User, 2024-2034
Figure 120: South Asia and Pacific Market Attractiveness by Country, 2024-2034
Figure 121: East Asia Market Value (US$ Million) by Test, 2024-2034
Figure 122: East Asia Market Value (US$ Million) by Sample, 2024-2034
Figure 123: East Asia Market Value (US$ Million) by End User, 2024-2034
Figure 124: East Asia Market Value (US$ Million) by Country, 2024-2034
Figure 125: East Asia Market Value (US$ Million) Analysis by Country, 2019-2034
Figure 126: East Asia Market Value Share (%) and BPS Analysis by Country, 2024-2034
Figure 127: East Asia Market Y-o-Y Growth (%) Projections by Country, 2024-2034
Figure 128: East Asia Market Value (US$ Million) Analysis by Test, 2019-2034
Figure 129: East Asia Market Value Share (%) and BPS Analysis by Test, 2024-2034
Figure 130: East Asia Market Y-o-Y Growth (%) Projections by Test, 2024-2034
Figure 131: East Asia Market Value (US$ Million) Analysis by Sample, 2019-2034
Figure 132: East Asia Market Value Share (%) and BPS Analysis by Sample, 2024-2034
Figure 133: East Asia Market Y-o-Y Growth (%) Projections by Sample, 2024-2034
Figure 134: East Asia Market Value (US$ Million) Analysis by End User, 2019-2034
Figure 135: East Asia Market Value Share (%) and BPS Analysis by End User, 2024-2034
Figure 136: East Asia Market Y-o-Y Growth (%) Projections by End User, 2024-2034
Figure 137: East Asia Market Attractiveness by Test, 2024-2034
Figure 138: East Asia Market Attractiveness by Sample, 2024-2034
Figure 139: East Asia Market Attractiveness by End User, 2024-2034
Figure 140: East Asia Market Attractiveness by Country, 2024-2034
Figure 141: Middle East and Africa Market Value (US$ Million) by Test, 2024-2034
Figure 142: Middle East and Africa Market Value (US$ Million) by Sample, 2024-2034
Figure 143: Middle East and Africa Market Value (US$ Million) by End User, 2024-2034
Figure 144: Middle East and Africa Market Value (US$ Million) by Country, 2024-2034
Figure 145: Middle East and Africa Market Value (US$ Million) Analysis by Country, 2019-2034
Figure 146: Middle East and Africa Market Value Share (%) and BPS Analysis by Country, 2024-2034
Figure 147: Middle East and Africa Market Y-o-Y Growth (%) Projections by Country, 2024-2034
Figure 148: Middle East and Africa Market Value (US$ Million) Analysis by Test, 2019-2034
Figure 149: Middle East and Africa Market Value Share (%) and BPS Analysis by Test, 2024-2034
Figure 150: Middle East and Africa Market Y-o-Y Growth (%) Projections by Test, 2024-2034
Figure 151: Middle East and Africa Market Value (US$ Million) Analysis by Sample, 2019-2034
Figure 152: Middle East and Africa Market Value Share (%) and BPS Analysis by Sample, 2024-2034
Figure 153: Middle East and Africa Market Y-o-Y Growth (%) Projections by Sample, 2024-2034
Figure 154: Middle East and Africa Market Value (US$ Million) Analysis by End User, 2019-2034
Figure 155: Middle East and Africa Market Value Share (%) and BPS Analysis by End User, 2024-2034
Figure 156: Middle East and Africa Market Y-o-Y Growth (%) Projections by End User, 2024-2034
Figure 157: Middle East and Africa Market Attractiveness by Test, 2024-2034
Figure 158: Middle East and Africa Market Attractiveness by Sample, 2024-2034
Figure 159: Middle East and Africa Market Attractiveness by End User, 2024-2034
Figure 160: Middle East and Africa Market Attractiveness by Country, 2024-2034
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
What was the Value of the Newborn Metabolic Screening Market in 2019?
The newborn metabolic screening market was worth US$ 230.2 million in 2019.
How Big the Newborn Metabolic Screening Market is Estimated to Be in 2024?
The newborn metabolic screening market is likely to be valued at US$ 355.1 million in 2024.
What is the Demand Forecast for Newborn Metabolic Screening for the Decade?
The newborn metabolic screening market is expected to reach US$ 857.4 million by the end of 2034.
What is the Adoption Growth Projection for Newborn Metabolic Screening?
Adoption of newborn metabolic screening is projected to rise at a CAGR of 9.2% through 2034.
At What Rate Is the Newborn Metabolic Screening Market in North America Predicted to Grow?
The North America newborn metabolic screening market is forecast to register a CAGR of 9.4% through 2034.
Newborn Metabolic Screening Market